Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary troid Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.
[1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary troid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64.